JP2022550919A5 - - Google Patents

Info

Publication number
JP2022550919A5
JP2022550919A5 JP2022521584A JP2022521584A JP2022550919A5 JP 2022550919 A5 JP2022550919 A5 JP 2022550919A5 JP 2022521584 A JP2022521584 A JP 2022521584A JP 2022521584 A JP2022521584 A JP 2022521584A JP 2022550919 A5 JP2022550919 A5 JP 2022550919A5
Authority
JP
Japan
Prior art keywords
compound
use according
platelet count
treatment period
itp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022521584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550919A (ja
JP7795454B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/055410 external-priority patent/WO2021076514A1/en
Publication of JP2022550919A publication Critical patent/JP2022550919A/ja
Publication of JP2022550919A5 publication Critical patent/JP2022550919A5/ja
Priority to JP2025129327A priority Critical patent/JP2025163155A/ja
Application granted granted Critical
Publication of JP7795454B2 publication Critical patent/JP7795454B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022521584A 2019-10-14 2020-10-13 (r)-2-[3-[4-アミノ-3-(2-フルオロ-4-フェノキシ-フェニル)ピラゾロ[3,4-d]ピリミジン-1-イル]ピペリジン-1-カルボニル]-4-メチル-4-[4-(オキセタン-3-イル)ピペラジン-1-イル]ペンタ-2-エンニトリルを投与することにより免疫性血小板減少症を治療する方法 Active JP7795454B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025129327A JP2025163155A (ja) 2019-10-14 2025-08-01 (r)-2-[3-[4-アミノ-3-(2-フルオロ-4-フェノキシ-フェニル)ピラゾロ[3,4-d]ピリミジン-1-イル]ピペリジン-1-カルボニル]-4-メチル-4-[4-(オキセタン-3-イル)ピペラジン-1-イル]ペンタ-2-エンニトリルを投与することにより免疫性血小板減少症を治療する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962914688P 2019-10-14 2019-10-14
US62/914,688 2019-10-14
US201962951302P 2019-12-20 2019-12-20
US62/951,302 2019-12-20
PCT/US2020/055410 WO2021076514A1 (en) 2019-10-14 2020-10-13 Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025129327A Division JP2025163155A (ja) 2019-10-14 2025-08-01 (r)-2-[3-[4-アミノ-3-(2-フルオロ-4-フェノキシ-フェニル)ピラゾロ[3,4-d]ピリミジン-1-イル]ピペリジン-1-カルボニル]-4-メチル-4-[4-(オキセタン-3-イル)ピペラジン-1-イル]ペンタ-2-エンニトリルを投与することにより免疫性血小板減少症を治療する方法

Publications (3)

Publication Number Publication Date
JP2022550919A JP2022550919A (ja) 2022-12-05
JP2022550919A5 true JP2022550919A5 (cg-RX-API-DMAC7.html) 2023-10-20
JP7795454B2 JP7795454B2 (ja) 2026-01-07

Family

ID=73040359

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521584A Active JP7795454B2 (ja) 2019-10-14 2020-10-13 (r)-2-[3-[4-アミノ-3-(2-フルオロ-4-フェノキシ-フェニル)ピラゾロ[3,4-d]ピリミジン-1-イル]ピペリジン-1-カルボニル]-4-メチル-4-[4-(オキセタン-3-イル)ピペラジン-1-イル]ペンタ-2-エンニトリルを投与することにより免疫性血小板減少症を治療する方法
JP2025129327A Pending JP2025163155A (ja) 2019-10-14 2025-08-01 (r)-2-[3-[4-アミノ-3-(2-フルオロ-4-フェノキシ-フェニル)ピラゾロ[3,4-d]ピリミジン-1-イル]ピペリジン-1-カルボニル]-4-メチル-4-[4-(オキセタン-3-イル)ピペラジン-1-イル]ペンタ-2-エンニトリルを投与することにより免疫性血小板減少症を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025129327A Pending JP2025163155A (ja) 2019-10-14 2025-08-01 (r)-2-[3-[4-アミノ-3-(2-フルオロ-4-フェノキシ-フェニル)ピラゾロ[3,4-d]ピリミジン-1-イル]ピペリジン-1-カルボニル]-4-メチル-4-[4-(オキセタン-3-イル)ピペラジン-1-イル]ペンタ-2-エンニトリルを投与することにより免疫性血小板減少症を治療する方法

Country Status (12)

Country Link
US (3) US20210106584A1 (cg-RX-API-DMAC7.html)
EP (1) EP4045051A1 (cg-RX-API-DMAC7.html)
JP (2) JP7795454B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220080179A (cg-RX-API-DMAC7.html)
CN (1) CN115209899A (cg-RX-API-DMAC7.html)
AU (2) AU2020365951B2 (cg-RX-API-DMAC7.html)
CA (1) CA3154257A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022006087A2 (cg-RX-API-DMAC7.html)
IL (1) IL291994A (cg-RX-API-DMAC7.html)
MX (2) MX2022004427A (cg-RX-API-DMAC7.html)
TW (1) TWI877239B (cg-RX-API-DMAC7.html)
WO (1) WO2021076514A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL263815B (en) 2016-06-29 2022-07-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile
AU2020365951B2 (en) 2019-10-14 2026-07-16 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
KR102993352B1 (ko) 2019-12-20 2026-07-22 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태
WO2021150723A1 (en) 2020-01-22 2021-07-29 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
EP4322957A1 (en) * 2021-04-16 2024-02-21 Principia Biopharma Inc. Methods for treating drug and vaccine induced immune thrombocytopenia by administering specific compounds
EP4611755A1 (en) * 2022-10-31 2025-09-10 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-l-yl]pent-2-enenitrile
AU2024306785A1 (en) * 2023-06-30 2026-02-19 Principia Biopharma Inc. Methods for treating persistent or chronic immune thrombocytopenia in children, adolescents and adults by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy- phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4- methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2535721A1 (fr) 1982-11-08 1984-05-11 Sanofi Sa Derives de la piperidinedione protecteurs du myocarde presentant une acticite antiarythmique, leur procede de preparation et les medicaments qui contiennent lesdits derives
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2518353B2 (ja) 1988-06-09 1996-07-24 住友化学工業株式会社 シアノ酢酸アミド誘導体およびその製造中間体
CA2018801C (en) 1990-06-12 2000-08-22 Pierre Louis Beaulieu Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus
JPH04177244A (ja) 1990-11-10 1992-06-24 Konica Corp ハロゲン化銀写真感光材料
CA2033447C (en) 1990-12-31 1999-08-31 Robert Deziel Synergistic combination for treating herpes infections
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
JPH05301838A (ja) 1991-10-15 1993-11-16 Mitsubishi Kasei Corp スチレン誘導体
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
JPH0827090A (ja) 1994-05-13 1996-01-30 Sumitomo Chem Co Ltd シアノ酢酸アミド誘導体、その用途およびその製造中間体
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
PL335839A1 (en) 1997-03-14 2000-05-22 Basf Ag Cycloalkylalkane carboxamides as well as their production and application
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
IL125947A0 (en) 1997-09-17 1999-04-11 American Cyanamid Co 3-(1,2-benzisothiazol- and isoxazol-5-yl)-2,4(1h,3h)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3)-pyrimidinone or thione herbicidal agents
DE69814122T2 (de) 1997-10-09 2004-03-18 Dexcel Pharma Technologies Ltd. Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
CA2366932C (en) 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
KR20020088406A (ko) 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
AU2000240570A1 (en) 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
JP3991812B2 (ja) 2001-12-11 2007-10-17 住友化学株式会社 エステル化合物およびその用途
AU2003210983A1 (en) 2002-02-11 2003-09-04 The Brigham And Women's Hospital, Inc. Kinase inhibitors and methods of use thereof
NI200300043A (es) 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0219024D0 (en) 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
GB0226370D0 (en) 2002-11-12 2002-12-18 Novartis Ag Organic compounds
JP2006518368A (ja) 2003-02-21 2006-08-10 ファイザー・インク プロテインキナーゼ阻害剤としてのn−ヘテロシクリル置換アミノチアゾール誘導体
WO2004100868A2 (en) 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
JP4727579B2 (ja) 2003-08-01 2011-07-20 中外製薬株式会社 マロニル−CoAデカルボキシラーゼ阻害剤として有用なシアノアミド化合物
KR20060115350A (ko) 2003-09-02 2006-11-08 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
WO2005023773A1 (en) 2003-09-04 2005-03-17 Pfizer Limited Process for the preparation of substituted aryl pyrazoles
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
BRPI0414798A (pt) 2003-09-25 2006-11-21 Warner Lambert Co métodos para usar aminoácidos com afinidade para a proteìna alfa2delta
WO2005074603A2 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
JP4552456B2 (ja) 2004-02-27 2010-09-29 住友化学株式会社 エステル化合物およびその用途
EP1724264A1 (en) 2004-03-10 2006-11-22 Ono Pharmaceutical Co., Ltd. Nitriles and medicinal compositions containing the same as the active ingredient
US7807719B2 (en) 2004-09-14 2010-10-05 Chaim Roifman Compounds useful for modulating abnormal cell proliferation
US20060079494A1 (en) 2004-09-27 2006-04-13 Santi Daniel V Specific kinase inhibitors
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US20080260818A1 (en) 2005-03-28 2008-10-23 Dexcel Pharma Technologies Ltd. Controlled Absorption of Statins in the Intestine
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US20080146643A1 (en) 2005-06-15 2008-06-19 Pfizer Limited Combination
EP1893581B1 (en) 2005-06-15 2010-01-27 Pfizer Limited Substituted arylpyrazoles for use against parasitites
US20070149464A1 (en) 2005-06-15 2007-06-28 Pfizer Inc. Combination
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
US20080176865A1 (en) 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
GB0517205D0 (en) 2005-08-22 2005-09-28 Novartis Ag Organic compounds
CA2623327A1 (en) 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
JP5193876B2 (ja) 2005-12-02 2013-05-08 バイエル・ヘルスケア・エルエルシー オーロラキナーゼの阻害により癌を処置するために有用なピロロトリアジン誘導体
KR20080098490A (ko) 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
WO2007115269A2 (en) 2006-03-31 2007-10-11 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
US7645748B2 (en) 2006-04-03 2010-01-12 Forbes Medi-Tech Inc. Sterol/stanol phosphorylnitroderivatives and use thereof
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
WO2008005954A2 (en) 2006-06-30 2008-01-10 The Board Of Regents Of The University Of Texas System Tryphostin-analogs for the treatment of cell proliferative diseases
RU2481336C2 (ru) 2006-07-06 2013-05-10 Эррэй Биофарма Инк. Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
WO2008054827A2 (en) 2006-11-03 2008-05-08 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
AU2007323335A1 (en) 2006-11-23 2008-05-29 Novartis Ag Pyrimidines and their use as CXCR2 receptor antagonists
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
GB2447933A (en) 2007-03-27 2008-10-01 Chemence Ltd Cyanoacrylate monomer for forming an adhesive polymer
EP2139487B1 (en) 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
ATE522536T1 (de) 2008-02-25 2011-09-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
RU2503676C2 (ru) 2008-02-25 2014-01-10 Ф.Хоффманн-Ля Рош Аг Пирролопиразиновые ингибиторы киназы
CA2722418C (en) 2008-05-13 2013-09-17 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
JP2011520986A (ja) 2008-05-22 2011-07-21 アムジエン・インコーポレーテツド タンパク質キナーゼ阻害薬としての複素環類
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
RU2011105768A (ru) 2008-08-01 2012-09-10 Биокрист Фармасьютикалз, Инк. (Us) Производные пиперидина в качестве ингибиторов jakз
US8450337B2 (en) 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
US20120028981A1 (en) 2008-11-05 2012-02-02 Principia Biopharma Inc. Kinase Knockdown Via Electrophilically Enhanced Inhibitors
US20100113520A1 (en) 2008-11-05 2010-05-06 Principia Biopharma, Inc. Kinase knockdown via electrophilically enhanced inhibitors
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
KR20120063515A (ko) 2009-09-09 2012-06-15 아빌라 테라퓨틱스, 인크. Pi3 키나제 억제제 및 이들의 용도
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CN102711765A (zh) 2009-11-16 2012-10-03 加利福尼亚大学董事会 激酶抑制剂
EP2571880A1 (en) 2010-05-20 2013-03-27 F.Hoffmann-La Roche Ag Pyrrolo [2, 3 - b]pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors
US8940725B2 (en) 2010-05-31 2015-01-27 Ono Pharmaceutical Co., Ltd. Purinone derivative
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
CN101880243A (zh) 2010-06-04 2010-11-10 贵阳柏丝特化工有限公司 一种含氟氰拟除虫菊酯化合物及其合成方法与用途
PH12013500246A1 (en) 2010-08-10 2019-10-11 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
BR112013010564B1 (pt) 2010-11-01 2021-09-21 Celgene Car Llc Compostos heterocíclicos e composições compreendendo os mesmos
WO2012158810A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
AU2012255860C1 (en) 2011-05-17 2015-12-10 Principia Biopharma Inc. Tyrosine kinase inhibitors
DK2710007T3 (da) 2011-05-17 2020-01-27 Principia Biopharma Inc Kinasehæmmere
US8828426B2 (en) 2011-06-07 2014-09-09 Zx Pharma, Llc Multiparticulate L-carnitine compositions and related methods
WO2013003629A2 (en) 2011-06-28 2013-01-03 Pharmacyclics, Inc. Methods and compositions for inhibition of bone resorption
KR20140048968A (ko) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
WO2013010869A1 (en) 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
CN103889987B (zh) 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
KR20140063700A (ko) 2011-09-20 2014-05-27 셀좀 리미티드 키나제 억제제로서의 피라졸로[4,3-c]피리딘 유도체
US20140303191A1 (en) 2011-10-19 2014-10-09 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
MA37711A1 (fr) 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
EP2858500A4 (en) 2012-06-08 2016-04-06 Biogen Ma Inc BRUTON TYROSINE KINASE HEMMER
CN104487441B (zh) 2012-06-18 2018-06-01 普林斯匹亚生物制药公司 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶
WO2014004707A1 (en) 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
US20150209432A1 (en) 2012-07-26 2015-07-30 Lupin Limited Pharmaceutical compositions of proton pump inhibitor
US9572811B2 (en) 2012-08-03 2017-02-21 Principia Biopharma Inc. Treatment of dry eye
SMT201900344T1 (it) 2012-09-10 2019-07-11 Principia Biopharma Inc Composti di pirazolopirimidina come inibitori di chinasi
US20150291554A1 (en) 2012-11-02 2015-10-15 Pfizer Inc. Bruton's Tyrosine Kinase Inhibitors
SG11201503459SA (en) 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
KR20150084923A (ko) 2012-11-15 2015-07-22 파마시클릭스, 인코포레이티드 키나제 억제제로서의 피롤로피리미딘 화합물
US20140142099A1 (en) 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
CN105007940B (zh) 2012-12-20 2017-08-25 宾夕法尼亚州研究基金会 与癌症治疗相关的方法和组合物
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
US20160113913A1 (en) 2013-04-19 2016-04-28 Takeda Pharmaceutical Company Limited Controlled-release drug formulation
SG11201605417QA (en) 2014-02-03 2016-08-30 Cadila Healthcare Ltd Heterocyclic compounds
KR20160124157A (ko) 2014-02-20 2016-10-26 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
SG11201704808VA (en) 2014-12-18 2017-07-28 Principia Biopharma Inc Treatment of pemphigus
HRP20230305T1 (hr) 2014-12-24 2023-05-26 Principia Biopharma Inc. Pripravci za ileo-jejunalnu dostavu lijeka
CN107427468B (zh) 2014-12-24 2022-02-25 普林斯匹亚生物制药公司 Btk抑制剂的部位特异性给药
EP3912979B1 (en) 2015-06-03 2026-03-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN105753863B (zh) 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
US10358446B2 (en) 2015-10-14 2019-07-23 Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors
IL263815B (en) 2016-06-29 2022-07-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile
US20210113568A1 (en) 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
CN110483521B (zh) 2018-05-14 2022-06-07 杭州和正医药有限公司 一种可逆共价布鲁顿酪氨酸激酶抑制剂、药物组合物及其应用
AU2020365951B2 (en) 2019-10-14 2026-07-16 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2021150723A1 (en) 2020-01-22 2021-07-29 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2022081512A1 (en) 2020-10-12 2022-04-21 Synubi Pharmaceuticals Llc Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors

Similar Documents

Publication Publication Date Title
AU2018357775B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
JP2023065398A (ja) リルゾールの舌下製剤
CN105263579B (zh) 左西替利嗪和孟鲁司特在治疗血管炎中的用途
JP2022516662A5 (cg-RX-API-DMAC7.html)
US20200101067A1 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
JP2013541583A (ja) 組み合わせ組成物
JP2022536623A (ja) 肺動脈性肺高血圧症の治療方法
CN107137417B (zh) 一种用于治疗恶病质的药物组合物及其应用
JP4007615B2 (ja) 自己免疫性疾患の処置用薬剤組成物
JP2019507786A5 (cg-RX-API-DMAC7.html)
TW201828937A (zh) 供治療重症肌無力及其他肌無力症候群之用途及組合物
JP2023536944A (ja) 疾患の治療におけるbtk阻害剤の使用
FI4199922T3 (fi) (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa
JP2026510948A (ja) 慢性閉塞性肺疾患患者におけるエンテロウイルスの治療方法
JP2022505184A5 (cg-RX-API-DMAC7.html)
JP2021075470A (ja) 肺線維症の予防または治療のための医薬
JP2022504435A5 (cg-RX-API-DMAC7.html)
JP7527662B2 (ja) ピモジドとメトトレキサートの医薬組成物、及びその使用
JP6420923B1 (ja) 医薬
JPH05310573A (ja) リウマチ治療薬
US20020198228A1 (en) Composition and method for the treatment of respiratory desease
TW202045184A (zh) 預防或治療肺纖維化的藥物
Hussar New Drugs 2021, Part 2
CN107708692A (zh) Aerd/哮喘中的血栓烷受体拮抗剂
WO2005063253A1 (ja) アレルギー症状治療用医薬組成物